Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.40 |
| ▸ | RHOA | P61586 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biphenyl SCHEMBL27609023 | 0.87 | CYP3A4 (0.55) | CYP3A4ALDH1A1NPSR1TSHRHSD17B10 | |
| Benzene SCHEMBL28238137 | 0.87 | CYP3A4 (0.50) | CYP3A4ALDH1A1NPSR1TSHRHSD17B10 | |
| Styrene SCHEMBL27482384 | 0.84 | CYP3A4 (0.51) | CYP3A4ALDH1A1NPSR1TSHRHSD17B10 | |
| Toluene SCHEMBL1852909 | 0.84 | CYP3A4 (0.51) | CYP3A4ALDH1A1NPSR1TSHRHSD17B10 | |
| Toluene SCHEMBL11320582 | 0.84 | CYP3A4 (0.51) | CYP3A4ALDH1A1NPSR1TSHRHSD17B10 | |
| Toluene SCHEMBL11320560 | 0.84 | CYP3A4 (0.51) | CYP3A4ALDH1A1NPSR1TSHRHSD17B10 | |
| Toluene SCHEMBL27819537 | 0.83 | NPSR1 (0.49) | CYP3A4ALDH1A1NPSR1TSHRHSD17B10 | |
| SCHEMBL23581251 | 0.83 | CYP3A4 (0.50) | CYP3A4ALDH1A1NPSR1TSHRHSD17B10 | |
| Toluene SCHEMBL1179811 | 0.83 | CYP3A4 (0.80) | CYP3A4ALDH1A1NPSR1TSHRHSD17B10 | |
| Toluene SCHEMBL28838013 | 0.81 | PKM (0.52) | CYP3A4ALDH1A1NPSR1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069374-B2 | CRYSTALLINE SOLVATES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL) METHYL) PHENYL)-D-GLUCITOL DERIVATIVES WITH ALCOHOLS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2021-07-28 | — | — | EP | disclosed |
| EP-3363807-B1 | PHARMACEUTICAL COMPOSITION COMPRISING CRYSTALLINE (2S,3R,4S,5S,6R)-2-[4-CHLORO-3-(4-ETHOXY-BENZYL)-PHENYL]-6-HYDROXYMETHYL-2-METHOXY-TETRAHYDRO-PYRAN-3,4,5-TRIOL (S)-PROPYLENE GLYCOL SOLVATE | ASTRAZENECA AB (SE) | 2019-11-13 | — | — | EP | disclosed |
| EP-3363807-A1 | PHARMACEUTICAL COMPOSITION COMPRISING CRYSTALLINE (2S,3R,4S,5S,6R)-2-[4-CHLORO-3-(4-ETHOXY-BENZYL)-PHENYL]-6-HYDROXYMETHYL-2-METHOXY-TETRAHYDRO-PYRAN-3,4,5-TRIOL (S)-PROPYLENE GLYCOL SOLVATE | AstraZeneca AB (SE) | 2018-08-22 | — | — | EP | disclosed |
| EP-3045466-B1 | (2S,3R,4S,5S,6R)-2-[4-CHLORO-3-(4-ETHOXY-BENZYL)-PHENYL]-6-HYDROXYMETHYL-2-METHOXY-TETRAHYDRO-PYRAN-3,4,5-TRIOL PROPYLENE GLYCOL SOLVATE AS SGT2 INHIBITOR FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2017-12-06 | — | — | EP | disclosed |
| US-9453039-B2 | Crystal structures of SGLT2 inhibitors and processes for preparing same | ASTRAZENECA AB (SE) | 2016-09-27 | — | — | US | disclosed |
| EP-3045466-A1 | (2S,3R,4S,5S,6R)-2-[4-CHLORO-3-(4-ETHOXY-BENZYL)-PHENYL]-6-HYDROXYMETHYL-2-METHOXY-TETRAHYDRO-PYRAN-3,4,5-TRIOL PROPYLENE GLYCOL SOLVATE AS SGT2 INHIBITOR FOR THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2016-07-20 | — | — | EP | disclosed |
| CN-103319445-B | Crystalline structure of SGLT2 inhibitor and preparation method thereof | ASTRAZENECA AB (SE) | 2016-01-20 | — | — | CN | disclosed |
| CN-103145773-B | Crystalline solvates and complexes of (IS) -1, 5-anhydro-L-C- (3- ( (phenyl) methyl) phenyl) -D-glucitol derivatives with amino acids as SGLT2 inhibitors for the treatment of diabetes | ASTRAZENECA AB | 2015-07-22 | — | — | CN | disclosed |
| US-9051399-B2 | Method for producing polar group-containing olefin copolymers | SHOWA DENKO K.K. (JP) | 2015-06-09 | — | — | US | disclosed |
| CN-104387354-A | Crystal structures and preparation methods of SGLT2 inhibitors | ASTRAZENECA AB | 2015-03-04 | — | — | CN | disclosed |
| EP-2457918-A2 | Crystalline solvates and complexes of (1s)-1,5-anhydro-1-c-(3-((phenyl) methyl) phenyl)-d-glucitol derivatives with amino acids as SGLT2 inhibitors for the treatment of diabetes | Bristol-Myers Squibb Company (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20110172176-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-14 | — | — | US | disclosed |
| US-7919598-B2 | Crystal structures of SGLT2 inhibitors and processes for preparing same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-05 | — | — | US | disclosed |
| CN-101479287-A | Crystalline solvates and complexes of (1S) -1, 5-anhydro-L-C- (3- ((phenyl) methyl) phenyl) -D-glucitol derivatives with amino acids as SGLT2 inhibitors for the treatment of diabetes | BRISTOL MYERS SQUIBB CO (US) | 2009-07-08 | — | — | CN | disclosed |
| CN-101468976-A | Crystal structure of SGLT2 inhibitor and preparation method thereof | BRISTOL MYERS SQUIBB CO (US) | 2009-07-01 | — | — | CN | disclosed |
| EP-2069374-A1 | CRYSTALLINE SOLVATES AND COMPLEXES OF (IS) -1, 5-ANHYDRO-L-C- (3- ( (PHENYL) METHYL) PHENYL) -D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES | Brystol-Myers Squibb Company (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008002824-A1 | CRYSTALLINE SOLVATES AND COMPLEXES OF (IS) -1, 5-ANHYDRO-L-C- (3- ( (PHENYL) METHYL) PHENYL) -D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004336-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-03 | — | — | US | disclosed |
| EP-1345935-A2 | PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS | Warner-Lambert Company LLC (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002050070-A2 | PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172176-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | SLC5A2, SLC5A1, GLP1R | CYP3A4 445/4885ALDH1A1 735/4885NPSR1 1679/4885 |
| US-20080004336-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | SLC5A2, SLC5A1, GLP1R | CYP3A4 445/4885ALDH1A1 735/4885NPSR1 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.